Orchid Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹341 crore and net profit of ₹29 crore for the September 2026 quarter.
Orchid Pharma (NSE: ORCHPHARMA) closed at ₹960.40 on 20 Nov 2026, up 10.4% over the past year. Its market capitalisation is ₹5,751 crore and it trades at 109.8 times earnings.
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.